

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Yarom COHEN

Attn: Applications

Serial No.: National Stage Application based on
PCT/IL97/00301

Filed: March 11, 1999

For: PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SYNDROME X OF
REAVEN

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.56

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

BEST AVAILABLE COPY

Sir:

Pursuant to Rule 56, applicant hereby calls to the attention of the Patent Office the references listed on the attached PTO Form 1449.

Applicant presents these references so that the Patent Office may, in the first instance, determine any relevancy thereof to the presently claimed invention; see Beckman Instruments, Inc. v. Chemtronics, Inc., 439 F.2d 1369, 1380, 165 USPQ 355, 364 (5th Cir. 1970). Also see Patent Office Rules 104 and 106.

Applicant respectfully requests that these references be expressly considered during the prosecution of this application and made of record herein and appear among the "References Cited" on any patent to issue herefrom.

Respectfully submitted,

TPP:mat
Attorney Docket No.: TPP 30566

Thomas P. Pavelko
Registration No. 31,689

STEVENS, DAVIS, MILLER & MOSHER, L.L.P.
1615 L Street, N.W., Suite 850
Washington, D.C. 20036
Telephone: (202) 785-0100
Facsimile: (202) 408-5200 or (202) 408-5088

Date: March 11, 1999

FORM PTO-1449 U.S. Department of Commerce
(Rev. 4/92) Patent and Trademark Office

ATTY. DOCKET NO.
TPP 30566

SERIAL NO.
To be assigned

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT
YACOB COHEN

FILING DATE
March 11, 1999

GROUP
PCT Branch

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AG	4 1 0 0 1 5 3	07/78	Garsky			May 11, 1977
AG	4 1 5 9 2 6 3	06/79	Garsky			May 11, 1977

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO
0 3 7 4 0 8 9	06/90	EP			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AG	Phillips R.E. et al: "Effectiveness of SMS 201-995 . . ."; The Lancet, vol. 1, 1986, pages 713-715
AG	Boyle P.J. et al: "Octeotride reverses hyperinsulinaemia . . ."; Journal of Clinical Endocrinology and Metabolism; vol. 76, no. 3, 1993, pages 752-756
AG	Carretta, R. et al: "Reduction of blood pressure in . . ."; Journal of Hypertension Supplement; vol. 7, 1989, pages s196-s197
AG	Kirk, J.M.W. et al: "Somatostatin analogue in short . . ."; Archives of Disease in Childhood, vol. 63, no. 12, 1988, page 1493-1494
AG	Bluming A.Z. et al: "Successful treatment of unstable . . ."; The American Journal of Medicine, vol. 85, 1988, pages 872-874
AG	Raynor K et al: "Cloned somatostatin receptors . . ."; Molecular Pharmacology, vol. 43, no. 6, June 1993, pages 838-844
AG	Raynor K et al: "Characterization of cloned somatostatin . . ."; Molecular Pharmacology, vol. 44, no. 2, August 1993, pages 385-392
AG	Sirtori C.R. et al: "Re-evaluation of a biguanide, Metformin . . ."; Pharmacological Research, vol. 30, no. 3, 1994, pages 187-228
AG	Guillaume G. et al: "Syndrome X et medecine generale"; Revue Medicale de Bruxelles, vol. 16, no. 2, 1995
AG	Smith U.: "Clinical and therapeutical aspects of . . ."; Cardiovascular Risk Factors, vol. 3, no. 1, 1993, pages 67-73

EXAMINER ANSH GUPTA

DATE CONSIDERED 2/05/01

EXAMINER: Initial if citation is considered, draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.